‘Pitfalls to avoid when bringing an early-stage company forward’
On October 27, we are pleased to announce that Jonathan Gertler, Managing Partner and CEO of Back Bay Life Science Advisors, will host a Talk at the Square at BioInnovation Institute (BII).
Based on Jonathan’s vast experience ranging from working as an outside clinical advisor for early-stage life science companies to serving as a partner in an investment fund, he will share several strategies and tactics on how to approach and engage investors. He will provide hands-on examples and give a unique insight into the mindset of an investor; what do investors need to know, what do they look for in an early-stage start-up and which tools can be used to engage them?
Additionally, Jonathan will look at the fundraising process from the other side of the fence and share what he believes life science entrepreneurs should be aware of when they assess whether an investor syndicate is a good or bad fit for the company.
Finally, he will share valuable knowledge for life science entrepreneurs about valuation, negotiation, and how to ensure that you have a great fundraising process.
Program of the day
15.30 Doors open
16.00 Introduction to BII and the subject of the day: Bobby Soni, CBO at BII
16.10 Keynote speaker: Jonathan Gertler ‘Pitfalls to avoid when bringing an early-stage company forward’
16.40 Fireside chat with Bobby Soni and questions
17.00 Informal networking and closing reception
Please note that the event has free admittance with 70 tickets available. Please sign up quickly to secure your seat.
If you have registered for the event but cannot attend, please email email@example.com.
About Jonathan Gertler:
Jonathan P. Gertler, MD, has over 35 years of clinical and scientific experience, and extensive advisory work with biotechnology, medical device, diagnostic, and health care IT companies in both the private and public sectors.
He has founded several life sciences companies, including Antyllus Therapeutics, a development-stage biotechnology company focused on aortic diseases, and Optivio, a commercial-stage enterprise software platform for stress management and performance optimization. Dr. Gertler also founded Cardiovascular Technologies, an endovascular company that successfully exited in 2001.
Throughout his advisory career, Dr. Gertler has counseled companies on growth and liquidity strategies and has been responsible for significant aggregate consideration in M&A private and public equity for biotech, medtech, and HCIT companies. Before his advisory and consulting career and during the latter phases of his academic career, he was a venture partner at SV Life Sciences from 1997-2001 and is currently partner in BioVentures MedTech Growth Fund.